Admedus : Appoints New Chief Financial Officer

Admedus Ltd

ABN 35 088 221 078

ASX ANNOUNCEMENT

REGISTERED OFFICE:

26 Harris Road Malaga Western Australia 6090

PO Box 6879

East Perth Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

Einfo.au@admedus.com www.admedus.com

• Corporate services relocating to Brisbane

• Biomanufacturing to remain in Perth

• New CFO with strong medical technology experience

Brisbane, Australia 26 August 2016

Admedus Limited (the Company) (ASX: AHZ) announced today that the Company will relocate corporate services functions to Brisbane, combining Finance, HR, IT and Customer Service with the commercial headquarters for its Infusion division and CardioCel® in the emerging markets. The award winning Biomanufacturing facility will remain in Perth.

Mr Wayne Paterson, Chair and Interim CEO said "Today's announcement is regarded as both a significant and essential development for Admedus as we scale our business to meet the demands of all of Admedus' stakeholders. This decision will take advantage of efficiency, collaboration and cohesion from having corporate services situated together with commercial operations."

The Company is pleased to announce the appointment of Mr Mark Ziirsen as its new Chief Financial Officer, to be based in Brisbane. Mr Ziirsen is a highly credentialed senior finance leader who joins Admedus from Cochlear Limited, where he has held the role of Director of Finance and IT for Asia Pacific for the past 5 years. He has a strong track record of delivering growth and significant operational improvements across a wide variety of industries (medical devices, technology and FMCG) and geographies (New Zealand, Pacific Islands, Indonesia, Sri Lanka, Hong Kong, Taiwan, Japan, South Korea, Vietnam, United States and Europe).

Mr Ziirsen's strong capabilities and experience in financial and business performance management are complimented by extensive corporate finance, M&A, financial control, investment decision making, risk management, strategy development and IT skills gained at leading organisations including Goodman Fielder, Coca-Cola Amatil and Aristocrat Leisure. Mr Ziirsen' qualifications include a Bachelor of Commerce, CPA designation and an MBA majoring in international business.

Current Chief Financial Officer and Company Secretary Mr Stephen Mann, who is based in Perth, has made a significant contribution to the Company over the past 5 years. He will continue to work with Admedus through this transition until the end of the year. The Company thanks Mr Mann for all his valuable work over the last 5 years.

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com

Blog: www.admedus.com/au/category/news/

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

FTI Consulting

Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

Rx Communications Group, LLC Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com